Transfusion and Apheresis Science
Volume 27, Issue 2 , Pages 167-173 , October 2002

Autologous peripheral blood stem cells (PBSC) in breast cancer

  • Franco Patrone

      Affiliations

    • Clinica di Medicina Interna I, DIMI, University of Genova and San Martino Hospital, 16132 Genoa, Italy
    • Corresponding Author InformationCorresponding author. Address: Department of Internal Medicine, University of Genova, Viale Benedetto XV n 6, 16132 Genoa, Italy. Tel.: +39-10-3538952; fax: +39-10-3537976
    • ,
  • Mauro Valbonesi

      Affiliations

    • Immunohematology Service, San Martino University Hospital, 16132 Genoa, Italy
    • ,
  • Alberto Ballestrero

      Affiliations

    • Clinica di Medicina Interna I, DIMI, University of Genova and San Martino Hospital, 16132 Genoa, Italy

References 

  1. Estève J. Facts and figures of cancer in the European Community. International Agency for research on Cancer, Lyon, 1993
  2. Office for National Statistics. Mortality, statistics, cause. No. 21, DH2 Series, HMSO, 1996
  3. Mick R, Begg CB, Antman KH, Korzun AH, Frei III E. Diverse prognosis in metastatic breast cancer: who should be offered alternative sinitial
  4. Buzdar AU, Kau SW, Hortobagyi GN, Ames FC. Therapies?. Breast Cancer Res. Treat. 1989;13:33–38 Holmes FA, Fraschini G, Hug V, Theriault RL, McNeese MD, Singletary SE. Clinical course of patients with breast cancer with ten or more positive nodes who were treated with doxorubicin-containing adjuvant therapy. Cancer. 1992;69:448–452
  5. Garcia-Carbonero R, Hidalgo M, Paz-Ares L, Calzas J, Gomez H, Guerra JA, et al.  Patient selection in high-dose chemotherapy trials: relevance in high-risk breast cancer. J. Clin. Oncol. 1997;15:3178–3184
  6. Antman K, Corringham R, de Vries E, Elfenbein G, Gianni AM, Gisselbrecht C, et al.  Dose intensive therapy in breast cancer. Bone Marrow Transplant. 1992;10(Suppl 1):67–73
  7. Peters WP, Dansey RD, Klein JL, Baynes . High-dose chemotherapy and peripheral blood progenitor cell transplantation in the treatment of breast cancer. The Oncol. 2000;5:1–13
  8. Weiss RB, Rifkin RM, Stewart FM, Theriault RL, Williams LA, Herman AA, et al.  High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet. 2000;355:999–1003
  9. Peters WP, Ross M, Vredenburgh JJ, Meisenberg B, Marks LB, Winer E, et al.  High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J. Clin. Oncol. 1993;11:1132–1143
  10. Gianni AM, Siena S, Bregni M, Di Nicola M, Orefice S, Cusumano F, et al.  Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J. Clin. Oncol. 1997;15:2312–2321
  11. Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, et al.  High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J. Clin. Oncol. 1997;15:1870–1879
  12. Rodenhuis S, Bontenbal M, Beex L. Randomized phase III study of high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin in operable breast cancer with 4 or more axillary lymph nodes. Proc. ASCO. 2000;19:74a; abstract 286
  13. Peters W, Rosner G, Vrendeburgh J. Updated results of a prospective, randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high-risk primary breast cancer involving ten or more axillary lymph nodes: CALBG 9082/SWOG 9114/NCIC Ma.13. Proc. ASCO. 2001;20: abstract 81
  14. Gianni A, Bonadonna G. Five-year results of the randomized clinical trial comparing standard versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes. Proc. ASCO. 2001;20: abstract 80
  15. Roche HH, Pouillart P, Meyer N. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: the Pegase 01 Trial. Proc. ASCO. 2001;20: abstract 102
  16. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, et al.  Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet. 1998;352:515–521
  17. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, Booser DJ, et al.  Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J. Nat. Cancer Inst. 2000;92:225–233
  18. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, Malmstrom P, et al.  Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial Scandinavian Breast Group 9401 study. Lancet. 2000;356:1384–1391
  19. Peters WP, Jones RB, Vredenburgh J. A large, prospective, randomized trial of high-dose combination alkylating agent (CPB) with autologous cellular support (ABMS) as consolidation for patients with metastatic breast cancer achieving complete remission after intensive doxorubicin-based induction therapy (AFM). Proc. ASCO. 1996;16:149a
  20. Lotz JP, Cure H, Janvier M. High dose chemotherapy with hematopoietic stem cell transplantation for metastatic breast cancer: results of the French protocol PEGASE 04. Proc. ASCO. 1999;18: abstract 161
  21. Stadtmauer EA, O'Neill A, Goldstein LJ, Crilley PA, Mangan KF, Ingle JN, et al.  Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N. Engl. J. Med. 2000;342:1069–1076
  22. Modan B, Broadwater G, Rubin P. Improved survival with consolidation high-dose cyclophosphamide, cisplatin and carmustine (Hd-Cpb) compared with observation in women with metastatic breast cancer (Mbc) and only bone metastases treated with induction adriamycin, 5-fluorouracil and methotrexate. Proc. ASCO. 2000;19: abstract 184
  23. Crump M, Gluck S, Stewart D. A randomized trial of high-dose chemotherapy (HDC) with autologous peripheral blood stem cell support (ASCT) compared to standard therapy in women with metastatic breast cancer: a national cancer institute of canada (NCIC) clinical trials group study. Proc. ASCO. 2001;20: abstract 82
  24. Diamond GA, Forrester JS. Clinical trials and statistical verdicts: probable grounds for appeal. Ann. Int. Med. 1983;98:385–394
  25. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, et al.  Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N. Engl. J. Med. 2000;342:525–533
  26. Solano C, Badia B, Lluch A, Marugan I, Benet I, Arbona C, et al.  Prognostic significance of the immunocytochemical detection of contaminating tumor cells (CTC) in apheresis products of patients with high-risk breast cancer treated with high-dose chemotherapy and stem cell transplantation. Bone Marrow Transplant. 2001;27:287–293
  27. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W. Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J. Clin. Oncol. 2001;19:3669–3674
  28. Ballestrero A, Coviello DA, Garuti A, Nencioni A, Famà A, Rocco I, et al.  Reverse-transcriptase polymerase chain reaction of the maspin gene in the detection of bone marrow breast cancer cell contamination. Cancer. 2001;92:2030–2035
  29. Siena S, Schiavo R, Pedrazzoli P, Carlo-Stella C. Therapeutic relevance of CD34+ cell dose in blood cell transplantation for cancer therapy. J. Clin. Oncol. 2000;18:1360–1377
  30. Patrone F, Ballestrero A, Ferrando F, Brema F, Moraglio L, Valbonesi M, et al.  Four-step high-dose sequential chemotherapy with double hematopoietic progenitor cell rescue for metastatic breast cancer. J. Clin. Oncol. 1995;13:840–846
  31. Ballestrero A, Ferrando F, Garuti A, Basta P, Gonella R, Stura P, et al.  Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF) and sequential interleukin-3 (IL-3) and GM-CSF. J. Clin. Oncol. 1999;17:1296–1303
  32. Ballestrero A, Clavio M, Ferrando F, Gonella R, Garuti A, Sessarego M, et al.  High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma. Int. J. Oncol. 2000;17:1007–1013
  33. Sargent DJ, Niedzwiecki D, O'Connell MJ, Schilsky RL. Recommendation for caution with irinotecan, fluorouracil, and leucovorin for colorectal cancer. N. Engl. J. Med. 2001;345:144–145
  34. Rosti G, Ferrante P. EBMT solid tumors working party and registry. 2000 Report

PII: S1473-0502(02)00039-3

Transfusion and Apheresis Science
Volume 27, Issue 2 , Pages 167-173 , October 2002

Article Tools